Canine23
$SES Yes — the main near-term catalyst is whether SES hits its 2026 full-year revenue guidance of $30–35M, and especially whether Q4 shows the acceleration management has promised.
The market will care about how SES gets there. The strongest outcome would be:
* Revenue near the high end of guidance
* Q4 clearly the strongest quarter
* Drone-cell revenue beginning to ramp
* Actual purchase orders or named customers
* Strong 2027 guidance
That would validate SES as a company moving from development and partnerships into real commercialization.
A miss would be more concerning if caused by delayed drone revenue or weak ESS growth.
So I’d rank the catalysts:
1. Q4/full-year guidance
2. Drone orders and production ramp
3. 2027 guidance
4. More Molecular Universe customers
5. NYSE $1 compliance
A strong Q4 plus bullish 2027 guidance could matter much more than another partnership announcement.
7
